Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 16, 2020
Daily News
September 16, 2020
- IPOs or Sale? Employee Motivation Depends on Exit Strategies of Investment Funds
September 16, 2020
- Ex-Health Minister Tamura Comes Back as MHLW Chief
September 16, 2020
- Japan Inks COVAX Pact with Optional Arrangement, Commits 17.2 Billion Yen Upfront
September 16, 2020
- Prescriptions for Respiratory Meds, Antibiotics Down Over 30% in August: Survey
September 16, 2020
- New Vice Health Minister Aiming to Get Coronavirus Drugs and Vaccines to Japanese People “as Quickly as Possible”
September 16, 2020
- Daiichi Sankyo Begins PII Study of ADC Patritumab for HER3-Positive Colorectal Cancer
September 16, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…